• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Your Practice

Physicians and Patients Take On – and Win – the “Post Polypectomy Surprise” Billing Controversy

image_pdfFavoriteLoadingFavorite

Organizing efforts led by physicians and advocacy groups have resulted in a new law removing a problematic barrier to colon cancer screening, and a big win for patients.  

Current Colorectal Cancer Screening Guidelines

Colorectal cancer (CRC) is still a major public health issue but is largely preventable. The USPSTF currently recommends

  • Asymptomatic adults ≥45 years
    • 50 to 75 years (A recommendation)
    • 45 to 49 years (B recommendation)
    • Selectively offer screening in adults 76 to 85 years (C recommendation)
  • Guidance refers to individuals who are at average risk of CRC
    • No family history of known genetic disorders predisposing to high lifetime risk of CRC (e.g., Lynch syndrome or familial adenomatous polyposis)
    • No personal history of IBD, previous adenomatous polyp, or previous CRC

Grade A and B recommendations take on special importance because they specify that doctors and other healthcare professionals should ‘offer to provide this service’

What’s the Good News Regarding Grade A and B USPSTF Recommendations?

The Affordable Care Act (ACA) addresses reimbursement for preventative care with a focus on key professional recommendations including those of USPSTF. This means that health insurance plans must provide coverage resulting in no out-of-pocket payments for patients.

What Went Wrong?

Even prior to the ACA, there have been efforts to reduce the financial burdens associated with colorectal cancer screening. Starting in 2002, the Screen for Life Act sought to increase reimbursement for colorectal cancer screening and diagnostic tests and waived the deductible for colorectal cancer screening tests. With the 2010 Affordable Care Act, financial barriers to CRC screening have slowly disappeared. However, an unintended quirk in the law brought sticker shock to asymptomatic patients if a worrisome polyp was actually removed during a colonoscopy screening procedure. Even though the polypectomy would be considered standard of care (and considered a positive outcome of the screening procedure), the procedure was now considered therapeutic. Known as the ‘post polypectomy surprise’, the waiver of cost-sharing goes away and patients would have unexpected bills.  This surprise expense was viewed as barrier to screening aside from being unfair to patients and physicians alike who are simply following best practices.

What Happened in January 2022?

The push back against the ‘post polypectomy surprise’ is an excellent example of how physicians can organize, along with the support of other advocacy groups, to address and reverse a problematic barrier to care. Once the billing issue became clear following the passage of the ACA, advocacy led to the passage of ‘The Removing Barriers to Colorectal Cancer Screening Act (S. 668; HR 1570)’. Thanks to these efforts, over the next eight years, starting on January 1, 2022, the Medicare beneficiary coinsurance that stands at 20% for when a polyp or other growth is found and removed as part of a screening colonoscopy or screening flexible sigmoidoscopy will be phased out to zero.  The eight-year phase arises from the pay-as-you-go rule, also known as PAYGO. It requires to pay for such legislation by reducing other entitlement spending or increasing other revenues with the goal of limiting any expansion of the budget deficit.

Physician societies and organizations spent years of effort and resources to remove this barrier to care. Enactment of the ACA is associated with a significant 23% reduction in colorectal cancer cases and deaths. Dr. David Greenwald, President of the American College of Gastroenterology stated the following which should be a clarion call to physicians of all specialties about taking a stand on behalf of our patients

On behalf of the American College of Gastroenterology, I want to thank Congress for including the Removing Barriers to Colorectal Cancer Screening Act (S. 668; HR 1570) in the larger spending and COVID-19 relief packages today. This legislation is long overdue and will help increase colorectal cancer screening rates in the Medicare population. Thank you, Rep. Donald Payne, Jr. (D-NJ), Sen. Sherrod Brown (D-OH), and all current and former members of the U.S. Congress for championing this important bipartisan issue throughout the years. ACG is grateful to partner with many patient advocacy groups and professional societies, who have all joined together to get this passed through Congress

Colorectal cancer is still a major public health issue, yet still is largely preventable. Over 50,000 Americans are estimated to die from colorectal cancer this year. It does not take a pause due to COVID-19, or any other public health crisis. Thus, it is important for policy makers to do everything we can do to incentivize and increase colorectal cancer screening rates in the Medicare population

Learn More – Primary Sources:

H.R.1570: Removing Barriers to Colorectal Cancer Screening Act of 2020

Impact of the Affordable Care Act on Colorectal Cancer Incidence and Mortality (Lee et al. Am J Prev Med, 2022)

Congress Passes the Removing Barriers to Colorectal Cancer Screening Act – American College of Gastroenterology (gi.org)

Proposed Medicare rule includes good news for GI procedure reimbursement – American Gastroenterological Association

Want to stay on top of key guidelines and research papers?

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Your Practice Posts

Legal Disclaimer Click To Expand

This website (the “Website”) is a service made available by The ObG Project LLC, its partners, affiliates or subsidiaries (“Provider”). This Website provides general information related to the law and is designed to help users safely cope with their own legal needs. This website does not provide legal advice and Provider is not a law firm. None of our customer service representatives are lawyers and they also do not provide legal advice. Although we go to great lengths to make sure our information is accurate and useful, we recommend you consult a lawyer if you want legal advice. No attorney-client or confidential relationship exists or will be formed between you and Provider or any of our representatives.
This website is not intended to be a source for legal advice, and thus the reader should not rely on any information provided in this website as such. Readers should not consider the information provided to be an invitation for an attorney-client relationship, and should always seek the advice of competent counsel in the reader’s home jurisdiction. Provider may provide links to third party websites. These links are provided only as a convenience. Linked websites are not reviewed, controlled or examined by Provider and Provider is not responsible for the information, advertising, products, resources or other materials, of any linked site or any link contained in a linked site. The inclusion of any link does not imply endorsement by Provider. In addition, please be aware that your use of any linked site is subject to the terms and conditions applicable to that site. Please direct any questions regarding linked sites to the webmaster of that site.

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site